DAVITA INC. DVA
Unless otherwise indicated in this report "DaVita", "the Company" "we", "us", "our" and other similar terms refer to DaVita Inc. and its consolidated subsidiaries. Our annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports filed or furnished pursuant to section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, are made available free of charge through our website, located at http://www.davita.com, as soon as reasonably practicable after the reports are filed with or furnished to the Securities and Exchange Commission (SEC). The SEC also maintains a website at http://www.sec.gov where these reports and other information about us can be obtained. The contents of our website are not incorporated by reference into this report.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $13.64B | $12.82B | $12.14B | $11.61B | $11.62B | $11.55B | $11.39B | $10.71B | $10.09B | $9.73B |
| SG&A | $1.67B | $1.54B | $1.47B | $1.36B | $1.20B | $1.25B | $1.10B | $1.14B | $1.06B | $1.07B |
| Total operating expenses | $11.60B | $10.73B | $10.54B | $10.27B | $9.82B | $9.86B | $9.75B | $9.88B | $9.06B | $8.68B |
| Operating income | $2.04B | $2.09B | $1.60B | $1.34B | $1.80B | $1.69B | $1.64B | $1.53B | $1.81B | $2.03B |
| Pre-tax income | $1.35B | $1.53B | $1.18B | $966.3M | $1.52B | $1.32B | $1.20B | $1.05B | $1.40B | $1.62B |
| Income tax | $293.1M | $279.7M | $220.1M | $198.1M | $306.7M | $313.9M | $279.6M | $258.4M | $323.9M | $431.8M |
| Net income | $1.08B | $1.25B | $957.0M | $781.6M | $1.21B | $773.6M | $811.0M | $159.4M | $663.6M | $879.9M |
| EPS, basic | 10.06 | 11.02 | 7.62 | 6.03 | 9.30 | 6.46 | 5.29 | 0.93 | 3.52 | 4.36 |
| EPS, diluted | 9.84 | 10.73 | 7.42 | 5.85 | 8.90 | 6.31 | 5.27 | 0.92 | 3.47 | 4.29 |
| Shares, diluted (wtd. avg.) | $75.9M | $87.3M | $93.2M | $95.8M | $109.9M | $122.6M | $153.8M | $172.4M | $191.3M | $204.9M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $676.4M | $794.9M | $464.6M | $339.0M | $555.0M | $501.8M | $1.21B | $415.4M | $518.9M | $683.5M |
| Short-term investments | $24.3M | $51.1M | $11.6M | $77.7M | $22.3M | $20.1M | $11.6M | $2.9M | $32.8M | $307.0M |
| Receivables | $2.41B | $2.15B | $1.99B | $2.13B | $1.96B | $1.82B | $1.80B | $1.86B | $1.71B | $1.50B |
| Inventory | $160.6M | $134.6M | $143.1M | $109.1M | $107.4M | $111.6M | $97.9M | $107.4M | $181.8M | $160.4M |
| Total current assets | $4.06B | $3.75B | $3.14B | $3.16B | $3.17B | $3.15B | $3.69B | $8.42B | $8.77B | $3.99B |
| Property, plant and equipment | $2.81B | $2.94B | $3.07B | $3.26B | $3.48B | $3.52B | $3.47B | $3.39B | $3.15B | $2.86B |
| Goodwill | $7.55B | $7.38B | $7.11B | $7.08B | $7.05B | $6.92B | $6.79B | $6.84B | $6.61B | $6.02B |
| Other intangibles | $222.1M | $197.4M | $203.2M | $182.7M | $177.7M | $166.6M | $135.7M | $118.8M | $113.8M | $73.5M |
| Total assets | $17.48B | $17.29B | $16.89B | $16.93B | $17.12B | $16.99B | $17.31B | $19.11B | $18.97B | $18.76B |
| Accounts payable | $696.1M | $547.2M | $514.5M | $479.8M | $402.0M | $434.3M | $403.8M | $463.3M | $509.1M | $456.6M |
| Total current liabilities | $3.14B | $2.97B | $2.64B | $2.62B | $2.40B | $2.48B | $2.37B | $4.89B | $3.07B | $2.71B |
| Total liabilities | $16.32B | $15.19B | $14.15B | $14.70B | $14.75B | $14.09B | $13.81B | $14.08B | $13.08B | $12.93B |
| Retained earnings | -$328.4M | $1.53B | $598.3M | $174.5M | $354.3M | $852.5M | $1.43B | $2.74B | $3.63B | $3.71B |
| Total equity | -$651.1M | $121.1M | $1.06B | $712.3M | $755.5M | $1.38B | $2.13B | $3.70B | $4.69B | $4.65B |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $1.89B | $2.02B | $2.06B | $1.56B | $1.93B | $1.98B | $2.07B | $1.77B | $1.91B | $1.97B |
| Depreciation and amortisation | $708.3M | $716.4M | $736.5M | $721.1M | $667.8M | $616.6M | $600.9M | $574.8M | $544.1M | $494.9M |
| Stock-based compensation | $140.0M | $102.8M | $112.4M | $95.4M | $102.2M | $91.5M | $67.8M | $73.1M | $35.1M | $38.3M |
| Capital expenditure | $575.9M | $555.4M | $568.0M | $603.4M | $641.5M | $674.5M | $766.5M | $987.1M | $905.2M | $829.1M |
| Investing cash flow | -$654.9M | -$771.4M | -$771.8M | -$630.3M | -$784.7M | -$825.4M | $3.00B | -$1.01B | -$1.36B | -$1.20B |
| Financing cash flow | -$1.37B | -$816.9M | -$1.17B | -$1.12B | -$1.08B | -$1.85B | -$4.70B | -$625.4M | -$766.3M | -$1.35B |
| Dividends paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | — |
| Buybacks | $1.31B | $1.39B | $272.2M | $802.2M | $1.54B | $1.46B | $2.38B | $1.16B | $802.9M | $1.10B |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0000927066-26-000053.
Others in SIC 8090
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| SHC | Sotera Health Co | $5.39B | 70.0x | 5.7% |
| PGNY | Progyny, Inc. | $1.99B | 39.9x | 10.4% |
| AGL | agilon health, inc. | $1.49B | — | -2.1% |
| VMD | VIEMED HEALTHCARE, INC. | $345.8M | 24.5x | 20.5% |
| CCEL | CRYO CELL INTERNATIONAL INC | $34.5M | — | -1.3% |
| MGRX | MANGOCEUTICALS, INC. | $8.9M | — | -26.0% |
| BRTX | BioRestorative Therapies, Inc. | $3.8M | — | -10.3% |
| FMS | Fresenius Medical Care AG | — | — | — |